SCHEMBL4606305

SCHEMBL4606305

CCC(=O)Nc1ccc(/C=C/c2ccccc2F)cc1C(=O)O

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNA3 P22001 1/20 0.46
NFE2L2 Q16236 5/20 0.45
KDM4E B2RXH2 2/20 0.42
ALDH1A1 P00352 2/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
MEN1 O00255 1/20 0.42
KMT2A Q03164 1/20 0.42
ADORA3 P0DMS8 2/20 0.42
RAB9A P51151 2/20 0.41
NPC1 O15118 1/20 0.41
PKM P14618 1/20 0.41
DHODH Q02127 2/20 0.41
SNCA P37840 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
PTPN1 P18031 1/20 0.40
HNF4A P41235 1/20 0.40
LCK P06239 1/20 0.40
ADORA2A P29274 1/20 0.39
ADORA2B P29275 1/20 0.39
ADORA1 P30542 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4606313 1.00 KCNA3 (0.46) KCNA3NFE2L2KDM4EALDH1A1SMN1; SMN2
SCHEMBL1825893 0.87 NFE2L2 (0.46) NFE2L2KDM4EALDH1A1SMN1; SMN2MEN1
SCHEMBL1825897 0.87 NFE2L2 (0.46) NFE2L2KDM4EALDH1A1SMN1; SMN2MEN1
SCHEMBL4604654 0.86 ADORA3 (0.54) KDM4EALDH1A1SMN1; SMN2MEN1KMT2A
SCHEMBL4604659 0.86 ADORA3 (0.54) KDM4EALDH1A1SMN1; SMN2MEN1KMT2A
SCHEMBL1825739 0.85 KDM4E (0.49) NFE2L2KDM4EALDH1A1SMN1; SMN2MEN1
SCHEMBL1825743 0.85 KDM4E (0.49) NFE2L2KDM4EALDH1A1SMN1; SMN2MEN1
SCHEMBL4605447 0.85 BACE1 (0.46) KDM4EALDH1A1SMN1; SMN2MEN1KMT2A
SCHEMBL4605442 0.85 BACE1 (0.46) KDM4EALDH1A1SMN1; SMN2MEN1KMT2A
SCHEMBL1824375 0.85 KDM4E (0.57) KCNA3KDM4EALDH1A1SMN1; SMN2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-1914152-B New compounds, methods for their preparation and use thereof ACTIVE BIOTECH AB 2010-06-09 CN disclosed
EP-1720825-B1 ANTHRANILIC ACID DERIVATIVES, METHODS FOR THEIR PREPARATION AND USE AS DHODH INHIBITORS ACTIVE BIOTECH AB (SE) 2008-07-09 EP disclosed
CN-1914152-A New compounds, methods for their preparation and use thereof ACTIVE BIOTECH AB (SE) 2007-02-14 CN disclosed
EP-1720825-A1 NEW COMPOUNDS, METHODS FOR THEIR PREPARATION AND USE THEREOF Active Biotech AB (SE) 2006-11-15 EP disclosed
US-7074831-B2 Compounds, methods for their preparation and use thereof ACTIVE BIOTECH AB (SE) 2006-07-11 US disclosed
US-20050187297-A1 New compounds, methods for their preparation and use thereof ACTIVE BIOTECH AB (SE) 2005-08-25 US disclosed
WO-2005075410-A1 NEW COMPOUNDS, METHODS FOR THEIR PREPARATION AND USE THEREOF ACTIVE BIOTECH AB (SE) 2005-08-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050187297-A1 New compounds, methods for their preparation and use thereof MALT1, TPMT, FUCA1 KCNA3 4320/4885NFE2L2 1096/4885KDM4E 2898/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.